閱文(00772.HK)績後挫逾8% 今年至少6劇及兩套電影上映
閱文集團(00772.HK)去年純利增長32%,經調整純利跌16.2%至11.3億元人民幣,不派息。今日(19日)股價高開1.5%後掉頭回落,現報25.05元,跌8.41%,成交139.16萬股,涉資3,616.72萬元。
閱文首席執行官侯曉楠在記者會上表示,今年將是公司「爆款之年」,將有6至7套電視劇推出,以及2套電影上映。另外,多個授權改編的IP遊戲項目包括《斗羅大陸》及《斗破蒼穹》等亦已獲得遊戲版號,有望在今年推出。
侯氏續指,今年會繼續關注營運效率以及營銷投資回報率,若投資回報率較佳,公司將考慮投入。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.